ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements
NSE rejected Gufic Biosciences' waiver application regarding a ₹1.72 lakh penalty for Regulation 17(1A) non-compliance. The company will pay the fine by October 03, 2026.
Gufic Biosciences announced that CRISIL Ratings has reaffirmed its credit ratings on the company's total bank loan facilities of ₹516 Crore.
Gufic Biosciences held its 42nd Annual General Meeting on September 4, 2026, where shareholders adopted financial statements and approved the final dividend declaration.
Gufic Biosciences Limited announced the promotions of Ms. Ami Shah to Head-Legal and Mr. Pinak Padhya to President of Sales & Marketing, effective September 2, 2026.
Gufic reports strong Q1 FY27 growth, driven by Indore plant ramp-up and expansion into high-margin complex injectables like GLP-1 (Semaglutide) and Botulinum Toxin.
Gufic reported Q1 FY27 revenue of ₹260.8 Cr (+15% YoY) with EBITDA margins expanding to 18.09%. Strategy pivots toward IP-owned complex injectables and scaling the new Indore facility.
Gufic BioSciences Ltd reported revenue from operations of ₹260.8 Cr (+16.6% YoY) and net profit of ₹22.3 Cr (+70.2% YoY) for Q1 FY27.
Gufic delivered record Q4 FY26 revenue of ₹252cr with EBITDA margins expanding to 17.7%. Management is pivoting to an IP-led international model and scaling the new Indore facility.
Gufic delivered its strongest ever quarter in Q4FY26, driven by Indore facility break-even and a strategic shift in the international business model towards holding its own marketing authorizations.
Gufic Biosciences reported Q4 FY26 revenue of ₹252.1 cr and PAT of ₹20.5 cr. Strategy focuses on scaling the Indore facility and transitioning to an IP-owned international model.
Gufic BioSciences Ltd reported revenue from operations of ₹251.8 Cr (+22.8% YoY) and net profit of ₹21.9 Cr (+184.4% YoY) for Q4 FY26.